AzTrials
AzTrials

Hepatitis BPhase 4NCT06786429

Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.

A Phase 4 study testing Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV) and Cognitive Behavioral Therapy in people with Hepatitis B and Human Papilloma Virus, run by Eunice Dube.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record

Search all trials

Trial summary

Aim: The main goal of this quantitative epidemiological observational study is to determine the prevalence of Human Papilloma Virus (HPV) infection and Hepatitis B (Hep B) immunity amongst women of childbearing age. Read more about this study

Who is it for?
Ages 13 to 50 yearsHealthy volunteers can take part
What is being tested?
Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV) and Cognitive Behavioral Therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2,140 participants
Where
No sites listed yet
Study dates
30 Jan 2027to 15 Dec 2032
Phase
Phase 4

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 13 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Who may be able to join

  • For the High school students' group:
  • All students aged 13 years and older, enrolled at the selected Mtshabezi and Matopo High Schools in the Gwanda and Matobo Rural Districts during the five years of the project, are eligible to participate in the study.
  • Ability to understand and respond to questions on the Youth Risk Behavior Survey questionnaire and PHQ-9 scale.
  • Relevant history of HPV vaccine administration. Ability to obtain parental/guardian consent for participation.
  • For the women's group: All women and young female adults, thirteen to fifty years old, and requesting health services for prenatal, post-partum, family planning, and other care during the five-year project period are eligible to participate.
  • Can understand and respond to the PHQ-9 and Edinburgh Postnatal Depression scales.
  • Must have a valid consent for participation in the study.

Who cannot join

  • males who are not enrolled in these participating High Schools.
  • children below the age of thirteen who are not enrolled in high schools and are not seeking prenatal, post-partum, and family planning services at these selected health facilities during the project period.
  • Any eligible potential participant without a valid consent.
  • Any potential participant who is excluded by a doctor or midwife for a known contraindicating medical condition that can lead to potential harm to the participant or staff.
  • Any potential participant who is unable to understand and respond to the questions being asked.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Eunice Dube, DSc. contact

4437106077

eunicedube@comcast.net

Jill Koshiol, Ph. D. contact

2402767178

koshiolj@mail.nih.gov

About this study

Official title: Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers Among Women of Childbearing Age, and Young Adults in Zimbabwe in the Context of Mental Health: a Multimodal, Multifaceted Approach.

Aim: The main goal of this quantitative epidemiological observational study is to determine the prevalence of Human Papilloma Virus (HPV) infection and Hepatitis B (Hep B) immunity amongst women of childbearing age. attending clinics at Mtshabezi Mission and Matobo clinic respectively, and assessing behavioral risk factors of high school students at these catchment areas that can put them at risk for developing cancer of the cervix and liver.

Question: Can screening for cancer, vaccination against Hep B and HPV, and cognitive behavior intervention help in preventing related cancers amongst these groups of participants?

Read the detailed description

Hypotheses:

  • The prevalence of HPV infection (might be high) and Hep B immunity (might be low) is not documented and therefore unknown in this community, as there is no routine surveillance of these specific conditions
  • Behavioral risk factors of High School students in Matabeleland South Province have not yet been assessed and remain unaddressed, hence the high rates of suicide, infection, and teen pregnancy, which predispose participants to Hep B and HPV related infection and consequently, cancers. Participants have not had access to the HPV preventing vaccine Gardasil 9. To provide answers to these concerns, investigators propose the activity described below.

Objectives

The objectives of this proposal are twofold:

  1. Research- uses the Theory of Change and the quantitative epidemiologic descriptive survey method to gather, analyze, and interpret data and disseminate results. There is no sampling frame as this study is exploratory. True prevalences are not known.

1.1 Data collection, analysis, and interpretation to determine the burden of HPV infection; determine the HPV types that are prevalent in this community to assess the potential effectiveness of the available vaccine; assess the potential for developing a vaccine covering local Genotypes; determine the prevalence of immunity to Hep B, and depression prevalence among adult participants.1.2. Conduct a youth risk behavior screen to determine potential infection risk and mental health issues, and design intervention strategies.1.3 Disseminate preliminary findings after the first 6 months or year one and suggest intervention strategies that can be evaluated for effectiveness during the study period. Publish findings and scale project to other areas in Zimbabwe and internationally.1.4 Request collaboration with NIH/NCI/Global center/Behavioral health to strengthen research capabilities and service provision in this area.2. Intervention 2.1 Recruit 1140 consenting female participants attending prenatal, family planning, post-partum, and other clinics at these selected centers to perform a one-time comprehensive medical exam, pap smear (to detect abnormal cells, and HPV test (if eligible) to detect infection in the cervix); perform blood test to look for Hep. B. and cancer biomarkers' presence, perform a one-time fibro scan to assess the liver. 2.2 Administer the Youth Risk Behavior Screen (Centers for Disease Control and Prevention (CDC) to 1000 consenting students in the selected schools over a period of 5years to determine the types and significance of problem behavior and suggest appropriate interventions; Assess protective factors among boarders versus day scholars. offer the Gardasil 9 vaccine to 1000 eligible students with parental consent. 2.3 Refer participants with abnormal screens for further assessments and management, including behavioral health intervention as indicated. Assess potential for home visits, telehealth services, routine screening, and immunization to ease access to services. Create teen clinics at the school sites. Analyze data at three levels using the IBM Statistical Package for Social Sciences (SPSS) for significance testing and disseminate results. Solicit Ministry of Health and Childcare (MOHCC) buy-in for scaling to other Provinces.

  • Investigators plan to follow up this cohort for ten years post-vaccination
  • Based on the data obtained, clinical trials will assess the probability of developing an HPV vaccine that is user and patient-friendly to Low to Middle Income Countries (LMIC); promote creation and use of screening tools suitable for rural communities.
  • Participants identified as having risk behaviors will be offered further assessment by a psychiatrist or /and/or psychologist to develop a viable framework to prevent and manage such behaviors, including medication, which is currently not available in Zimbabwe.

Recommendations regarding women's health, i.e., screening for cervical cancer and vaccination against HPV and Hep B, depression, and Intimate Partner Violence will be guided by the findings of this study.

Being tested
Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV), Cognitive Behavioral Therapy
Medical subject headings
Hepatitis B, Carcinoma, Hepatocellular, Uterine Cervical Neoplasms, Depression, Anxiety Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Gardasil 9 vaccineBiological

    Participants with a valid consent will be offered a three-dose Gardasil 9 series if eligible.

  • Hepatitis B Virus Vaccine(HBV)Biological

    Participants who do not demonstrate immunity to Hep B antibody marker in their blood, HBsAb and not HBsAg will be offered a three-dose series of Hep B. vaccine. A blood test will be done six months later to assess vaccine take i.e. immunity. Patients who demonstrate infection with Hep B virus will be referred to their doctor for further management.

  • Cognitive Behavioral TherapyBehavioural

    Participants who demonstrate signs and symptoms of depression and/or anxiety will be offered individual behavioral management services. This consists of weekly individual sessions by a trained therapist for 8 weeks with option for referral for further management depending on the outcome of the intervention. The positive outcome consists of a change in presenting symptoms determined after administration of the youth risk behavior screen for high school students, and PHQ-9, and Edinburgh post-natal depression screen for women respectively.

Study groups in NCT06786429
Study groupRoleWhat they receive
High School StudentsOtherAll high school students in the study area are eligible, approximately 1000 students. Consenting participants will complete a one-time Youth Risk Behavior Survey (CDC) and receive Cognitive Behavioral Therapy if indicated. Eligible and consenting participants will be offered a 3-dose series of Gardasil 9 to protect against HPV.
Receives: Biological: Gardasil 9 vaccine; Behavioral: Cognitive Behavioral Therapy
Women of childbearing age and young adults (13-50years old)OtherThis group is at highest risk for having exposure to cervical and liver cancer, depression and anxiety. Participants are unlikely to have had vaccines of interest, Hep B, and HPV, as their status is unknown due to a lack of screening and vaccination. Participants in this group with depressive/anxiety symptoms are likely to benefit from CBT intervention
Receives: Biological: Gardasil 9 vaccine; Biological: Hepatitis B Virus Vaccine(HBV); Behavioral: Cognitive Behavioral Therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Human Papilloma Virus infection

    Women will be screened for HPV infection at baseline, and post vaccine with Gardasil 9

    Measured: Baseline and 10 years post vaccination

  2. Hepatitis B immunity

    Women will be screened for Hep B immunity before and after receiving a three-shot series of Hep B vaccine.

    Measured: Baseline and six months to one year post vaccination.

  3. cancer of cervix

    Patients will be assessed for malignancy on cervix

    Measured: Baseline assessment and 10 years post vaccination with Gardasil 9.

  4. Cancer of the liver

    Patients will have a fibro scan to assess condition of liver at initial visit and post vaccination with Hep B.

    Measured: Baseline and six months to one year post vaccination with Hep B.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jan 2025
  2. Study start30 Jan 2027 (estimated)
  3. Primary completion15 Dec 2032 (estimated)
  4. Study completion15 Dec 2032 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Health services research
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
High school students and women of childbearing age are participating concurrently as separate groups
Masking
None (open label)
Enrolment
2,140 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06786429
Sponsor's protocol ID
EX8KG3L2Z649
Status last verified
Jul 2026
First submitted
13 Jan 2025
Last updated
30 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Only test results data with no participant identifying information will be shared.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in